Renal lithiasis and cardiovascular risk

Anabel Abib, Elisa E. del Valle, Gustavo Laham, Francisco R. Spivacow

Article ID: 1917
Vol 4, Issue 1, 2023
DOI: https://doi.org/10.54517/ccr.v4i1.1917
Received: 5 January 2023; Accepted: 21 February 2023; Available online: 9 March 2023;
Issue release: 30 June 2023

VIEWS - 3652 (Abstract)

Download PDF

Abstract

Renal lithiasis (RL) is a common disease whose prevalence has increased in recent years. It is now considered a systemic pathology, not limited to the kidney and urinary tract, but largely related to diabetes mellitus, obesity, arterial hypertension, hyperuricemia, hypercholesterolemia, and chronic kidney disease, all cardiovascular risk factors that are often linked to severe events such as stroke, coronary heart disease, or acute myocardial infarction. Numerous crosssectional studies and meta-analyses have demonstrated the association between these two entities. In this review we will attempt to demonstrate the mechanisms involved in the pathophysiology of RL and its relationship with cardiovascular disease. As mechanisms involved, three associations are mentioned. The first refers to oxidative stress and inflammation. The second association refers to the presence of lithogenic mechanisms that contribute to vascular calcification. The last theory is the already known association of obesity, metabolic syndrome, diabetes and HT, all risk factors for the development of RL as well as cardiovascular disease, remembering that RL is the cause, in 8%, of the development of chronic kidney disease, another risk factor for cardiovascular disease and death. In conclusion, the theory that RL is not a disease limited to the kidney and urinary tract, but a systemic disease, with a risk of cardiovascular events so severe that they can lead to death, is confirmed


Keywords

lithiasis; kidney stones; cardiovascular risk; cardiovascular events; risk factors.


References

1. Liu Y, Li S, Zeng Z, et al. Kidney stones and cardiovascular risk: a meta-analysis of cohort studies. Am J Kidney Dis. 2014;64[3]:402-10.

2. Scales CD, Smith AC, Hanley JM, et al. Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012;62[1]:160-5.

3. Serio A, Fraioli A. Epidemiology of nephrolithiasis. Nephron. 1999;81[Suppl 1]:26-30.

4. Pinduli I, Spivacow R, del Valle E, et al. Prevalence of urolithiasis in the autonomous city of Buenos Aires, Argentina. Urol Res. 2006;34[1]:8-11.

5. Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens. 2008;17[3]:304-9.

6. Elmfeldt D, Vedin A, Wilhelmsson C, et al. Morbidity in representative male survivors of myocardial infarction compared to representative population samples. J Chronic Dis.1976;29[4]:221-31.

7. Hu C, Chen Y, Huang P, et al. The association between urinary calculi and increased risk of future cardiovascular events: A nationwide population-based study. J Cardiol. 2016;67[5]:463-70.

8. Madore F, Stampfer MJ, Rimm EB, et al. Nephrolithiasis and risk of hypertension. Am J Hypertens. 1998;11[1 Pt 1]:46-53.

9. Madore F, Stampfer MJ, Willett WC, et al. Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis. 1998;32[5]:802-7.

10. Fabris A, Ferraro PM, Comellato G, et al. The relationship between calcium kidney stones, arterial stiffness and bone density: unraveling the stone-bone-vessel liaison. J Nephrol. 2015;28[5]:549-55.

11. Kim S, Chang Y, Sung E, et al. Association Between Sonographically Diagnosed Nephrolithiasis and Subclinical Coronary Artery Calcification in Adults. Am J Kidney Dis. 2018;71[1]:35-41.

12. Randall A. The origin and growth of renal calculi. Ann Surg. 1937;105[6]:1009-27. 13] Weller RO, Nester B, Cooke SA. Calcification in the human renal papilla: an electron-microscope study. J Pathol. 1972;107[3]:211-6.

13. Stoller ML, Meng MV, Abrahams HM, et al. The primary stone event: a new hypothesis involving a vascular etiology. J Urol. 2004;171[5]:1920-4.

14. Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010;25[5]:831-41.

15. Evan AP, Lingeman JE, Coe FL, et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003;111[5]:607-16.

16. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue- culture studies. Clin Exp Nephrol. 2004;8[2]:75-88.

17. Baggio B, Gambaro G, Ossi E, et al. Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis. J Urol. 1983;129[6]:1161-2.

18. Thamilselvan V, Menon M, Thamilselvan S. Oxalate-induced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2009;297[5]:F1399-410.

19. Zuo J, Khan A, Glenton PA, et al. Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-proline-induced hyperoxaluria in the male Sprague-Dawley rats. Nephrol Dial Transplant. 2011;26[6]:1785-96.

20. Khan SR. Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res. 2005;33[5]:349-57.

21. Toblli JE, Cao G, Casas G, et al. NF-kappaB and chemokine-cytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin-angiotensin system. Urol Res. 2005;33[5]:358-67.

22. Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein-1 [MCP-1] by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant. 2003;18[4]:664-9. 24] Umekawa T, Iguchi M, Uemura H, Khan SR. Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int. 2006;98[3]:656-60.

23. Khan SR. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res. 2012;40[2]:95-112.

24. Rodriguez-Iturbe B, Vaziri ND, Johnson RJ. Inflammation, angiotensin II, and hypertension. Hypertension. 2008;52[5]:e135; author reply e136.

25. Chung SS, Ho EC, Lam KS, et al. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol. 2003;14[8 Suppl 3]:S233-6.

26. Manea A. NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res. 2010;342[3]:325-39.

27. Steckelings UM, Rompe F, Kaschina E, et al. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol. 2009;23[6]:693-703.

28. Boström K. Insights into the mechanism of vascular calcification. Am J Cardiol. 2001;88[2A]:20E-22E. Received in original form: January 5, 2019 In corrected form: January 14, 2019 Final acceptance: January 23, 2019 Dr. Anabel Abib Instituto de Diagnóstico e Investigaciones Metabólicas [IDIM], Buenos Aires, Argentina e-mail: anabelabib@hotmail.com

29. Fraser JD, Price PA. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J Biol Chem. 1988;263[23]:11033-6.

30. Wang L, Raikwar N, Deng L, et al. Altered gene expression in kidneys of mice with 2,8-dihydroxyadenine nephrolithiasis. Kidney Int. 2000;58[2]:528-36.

31. Gao B, Yasui T, Itoh Y, et al. Polymorphism of matrix Gla protein gene is associated with kidney stones. J Urol. 2007;177[6]:2361-5.

32. Herrmann SM, Whatling C, Brand E, et al. Polymorphisms of the human matrix gla protein [MGP] gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20[11]:2386-93.

33. Lu X, Gao B, Liu Z, et al. A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene. 2012;511[2]:127-30.

34. Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008.

35. Shoag J, Tasian GE, Goldfarb DS, et al. The new epidemiology of nephrolithiasis. Adv Chronic Kidney Dis. 2015;22[4]:273-8.

36. Rendina D, De Filippo G, D’Elia L, et al. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J Nephrol. 2014;27[4]:371-6.

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Anabel Abib, Elisa E. del Valle, Gustavo Laham, Francisco R. Spivacow

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).